RAB6C

Summary

RAB6C (RAB6C, member RAS oncogene family, HGNC:16525) is a protein-coding gene on chromosome 2q21.1, encoding Ras-related protein Rab-6C (Q9H0N0). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes.

Enables GTPase activity. Involved in mitotic cell cycle; regulation of centrosome duplication; and response to xenobiotic stimulus. Located in Golgi apparatus; microtubule organizing center; and nucleoplasm.

Source: NCBI Gene 84084 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 45 total
• MANE Select transcript: NM_032144

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16525
Approved symbol	RAB6C
Name	RAB6C, member RAS oncogene family
Location	2q21.1
Locus type	gene with protein product
Status	Approved
Aliases	WTH3
Ensembl gene	ENSG00000222014
Ensembl biotype	protein_coding
OMIM	612909
Entrez	84084

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000410061

RefSeq mRNA: 1 — MANE Select: NM_032144 NM_032144

CCDS: CCDS46408

Canonical transcript exons

ENST00000410061 — 1 exons

Exon	Start	End
ENSE00001588213	129979666	129982738

Expression profiles

Bgee: expression breadth broad, 79 present calls, max score 74.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.4115 / max 68.4150, expressed in 1725 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
22493	5.3873	1725
22494	0.0242	8

Top tissues by expression

114 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.85	silver quality
endometrium	UBERON:0001295	70.17	gold quality
primary visual cortex	UBERON:0002436	65.45	gold quality
superior frontal gyrus	UBERON:0002661	64.44	gold quality
prefrontal cortex	UBERON:0000451	64.40	gold quality
Ammon’s horn	UBERON:0001954	62.37	gold quality
Brodmann (1909) area 9	UBERON:0013540	61.69	gold quality
corpus callosum	UBERON:0002336	61.55	gold quality
frontal cortex	UBERON:0001870	61.41	gold quality
putamen	UBERON:0001874	59.91	gold quality
cerebral cortex	UBERON:0000956	59.89	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	58.89	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	58.88	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	58.70	gold quality
substantia nigra	UBERON:0002038	58.49	gold quality
temporal lobe	UBERON:0001871	58.37	gold quality
amygdala	UBERON:0001876	58.28	gold quality
caudate nucleus	UBERON:0001873	57.65	gold quality
nucleus accumbens	UBERON:0001882	57.20	gold quality
hypothalamus	UBERON:0001898	57.01	gold quality
placenta	UBERON:0001987	56.89	gold quality
cortical plate	UBERON:0005343	56.60	gold quality
right frontal lobe	UBERON:0002810	56.44	gold quality
anterior cingulate cortex	UBERON:0009835	55.68	gold quality
endocervix	UBERON:0000458	55.52	gold quality
brain	UBERON:0000955	54.46	gold quality
lower esophagus	UBERON:0013473	53.85	gold quality
lower esophagus muscularis layer	UBERON:0035833	53.85	gold quality
uterine cervix	UBERON:0000002	52.23	gold quality
popliteal artery	UBERON:0002250	51.94	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.11

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

90 targeting RAB6C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-199A-3P	99.75	70.48	929
HSA-MIR-199B-3P	99.75	70.48	929
HSA-MIR-3129-5P	99.75	70.46	914
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-378A-5P	99.65	66.33	1311

Literature-anchored findings (GeneRIF, showing 7)

• The behavior of WTH3 in primary drug-resistant breast cancer epithelial cells was similar to that in a model system where epigenetic regulation of the WTH3 gene was linked to the MDR phenotype. (PMID:16267028)
• The negative role played by the WTH3 gene in MDR development is through its proapoptotic potential that is regulated by multiple mechanisms at the transcription level, and one of these mechanisms is linked to the p53 gene. (PMID:17426708)
• plays role in multi-drug resistance development;DNA methylation is one of its transcription regulatory mechanisms (PMID:18992151)
• RAB6C is a rare example of a recently emerged retrogene that has acquired the status of a new gene, encoding a functional protein with altered characteristics compared to Rab6A’. (PMID:20064528)
• Rab6A’(Q72L) was then purified to homogeneity and crystallized at 293 K. X-ray diffraction data were collected to a resolution of 1.9 A from a crystal belonging to space group P22(1)2(1) with unit-cell parameters a = 36.84, b = 96.78, c = 109.99 A (PMID:22949199)
• This is the first study to report hypermethylation of LRPPRC, RAB6C, and ZNF471 in squamous cell carcinoma of the tongue (PMID:28255813)
• Rab6c is a new target of miR218 that can promote the progression of bladder cancer. (PMID:34515321)

Cross-species orthologs

0 orthologs

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB22A (ENSG00000124209), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RABL2A (ENSG00000144134), RAB5A (ENSG00000144566), RAB19 (ENSG00000146955)

Protein

Protein identifiers

Ras-related protein Rab-6C — Q9H0N0 (reviewed: Q9H0N0)

Alternative names: Rab6-like protein WTH3

All UniProt accessions (1): Q9H0N0

UniProt curated annotations — full annotation on UniProt →

Function. The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. RAB6C may be involved in the regulation of centrosome duplication and cell cycle progression.

Subcellular location. Nucleus. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome.

Tissue specificity. Highest levels are found in fetal and adult brain, prostate, testis and spinal cord. Undetectable expression in adrenal gland, skeletal muscle, bone marrow, fetal, and adult liver, heart, salivary gland, and trachea. Detected in the HEK293, HEK293T, LNCaP, MCF-7, T-47D and EVSA-T cell lines (at protein level).

Domain organisation. Switch 1, switch 2 and the interswitch regions are characteristic of Rab GTPases and mediate the interactions with Rab downstream effectors. The switch regions undergo conformational changes upon nucleotide binding which drives interaction with specific sets of effector proteins, with most effectors only binding to GTP-bound Rab.

Miscellaneous. Primate-specific retrogene derived from isoform 2 of RAB6A transcript. Previously reported to exhibit GTP-binding affinity comparable to that of RAB6A. In contrast concludes that RAB6C is an inefficient GTP-binding.

Similarity. Belongs to the small GTPase superfamily. Rab family.

RefSeq proteins (1): NP_115520* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR050227	Rab	Family

Pfam: PF00071

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (25 total): binding site 17, short sequence motif 2, mutagenesis site 2, chain 1, region of interest 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H0N0-F1	73.09	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (17): 28; 39; 40; 42; 68; 71; 126; 127; 129; 157; 158; 23 …

Post-translational modifications (1): 82

Mutagenesis-validated functional residues (2):

Position	Phenotype
25	no gtp binding. no gtp binding; when associated with t-45.
45	no gtp binding; when associated with g-25.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 87 (showing top): BENPORATH_ES_WITH_H3K27ME3, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_CELL_CYCLE, GOCC_CENTROSOME, GOBP_REGULATION_OF_CENTROSOME_CYCLE, GGCAGTG_MIR3243P, GOBP_MITOTIC_CELL_CYCLE, LYF1_01, GOBP_PROTEIN_LOCALIZATION_TO_GOLGI_APPARATUS, AACTTT_UNKNOWN, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE

GO Biological Process (9): mitotic cell cycle (GO:0000278), intracellular protein transport (GO:0006886), retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890), intra-Golgi vesicle-mediated transport (GO:0006891), small GTPase-mediated signal transduction (GO:0007264), response to xenobiotic stimulus (GO:0009410), regulation of centrosome duplication (GO:0010824), retrograde transport, endosome to Golgi (GO:0042147), protein localization to Golgi membrane (GO:1903292)

GO Molecular Function (7): GTPase activity (GO:0003924), G protein activity (GO:0003925), GTP binding (GO:0005525), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (9): nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), centrosome (GO:0005813), cytosol (GO:0005829), endomembrane system (GO:0012505), ciliary basal body (GO:0036064), nucleus (GO:0005634), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
Golgi vesicle transport	2
cytoplasm	2
intracellular membrane-bounded organelle	2
microtubule organizing center	2
cell cycle	1
mitotic nuclear division	1
intracellular protein localization	1
protein transport	1
intracellular transport	1
intracellular signaling cassette	1
response to chemical	1
regulation of centrosome cycle	1
centrosome duplication	1
intercellular transport	1
endosomal transport	1
cytosolic transport	1
protein localization to Golgi apparatus	1
protein localization to membrane	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
nuclear lumen	1
endomembrane system	1
centriole	1
vacuole	1
plasma membrane	1
cilium	1
intracellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

820 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAB6C	VPS53	Q5VIR6	779
RAB6C	DAXX	Q9UER7	526
RAB6C	H3-3A	P06351	431
RAB6C	H3C1	P02295	418
RAB6C	H3C14	Q71DI3	370
RAB6C	H3-5	Q6NXT2	367
RAB6C	H3-4	Q16695	358
RAB6C	H3-7	Q5TEC6	358
RAB6C	H2AC20	Q16777	317
RAB6C	H2AC19	P20670	316
RAB6C	RINT1	Q6NUQ1	306
RAB6C	ZNF471	Q9BX82	290
RAB6C	RIC1	Q4ADV7	287
RAB6C	TBC1D3B	A6NDS4	278
RAB6C	GDI1	P31150	277

IntAct

23 interactions, top by confidence:

A	B	Type	Score
GDI1	RAB4A	psi-mi:“MI:0914”(association)	0.820
RAB8A	WDR91	psi-mi:“MI:0914”(association)	0.600
RAB6C	APBB2	psi-mi:“MI:0915”(physical association)	0.560
RAB6C		psi-mi:“MI:0915”(physical association)	0.560
RAB6C	PMP22	psi-mi:“MI:0915”(physical association)	0.560
RAB12	CHM	psi-mi:“MI:0914”(association)	0.530
RAB6B	SBF1	psi-mi:“MI:0914”(association)	0.530
RAB6B	RAB6A	psi-mi:“MI:0914”(association)	0.530
Bicdl2	RAB6C	psi-mi:“MI:0915”(physical association)	0.400
RAB10	RAB19	psi-mi:“MI:0914”(association)	0.350
RAB6B	SBF1	psi-mi:“MI:0914”(association)	0.350
RIMS1	KIF2A	psi-mi:“MI:0914”(association)	0.350
RAB6C	CCT6A	psi-mi:“MI:0914”(association)	0.350
RAB6C	HLA-DRB1	psi-mi:“MI:0914”(association)	0.350
RAB6C	CAPS	psi-mi:“MI:0914”(association)	0.350
RAB6C	araB	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (13): RAB6C (Affinity Capture-MS), CCT2 (Affinity Capture-MS), CCT6A (Affinity Capture-MS), RAB6C (Affinity Capture-MS), CCT6B (Affinity Capture-MS), RAB6C (Affinity Capture-MS), HSPA2 (Affinity Capture-MS), RAB6C (Proximity Label-MS), RAB6A (Cross-Linking-MS (XL-MS)), RAB6C (Affinity Capture-MS), RAB6C (Co-fractionation), RAB6C (Co-fractionation), Ccdc64b (Affinity Capture-Western)

ESM2 similar proteins: A2YEQ6, O35963, O74536, O95661, O95755, P25378, P35283, P35284, P51156, P52198, P97950, Q00246, Q02723, Q06AU4, Q08AT1, Q08E00, Q09178, Q14088, Q20365, Q29RR0, Q3SXC5, Q3UHC2, Q504M8, Q53S08, Q5H913, Q5JT25, Q5R615, Q5U1Y1, Q5ZHV1, Q62120, Q62689, Q64008, Q69XM7, Q6IQ22, Q75R65, Q7SZ59, Q7TN89, Q7Z444, Q8C0V7, Q8CAM5

Diamond homologs: A4FV54, A6QR46, M0RC99, O18333, O18334, O80501, P05712, P11023, P16976, P17608, P18066, P20336, P20339, P20340, P22127, P22128, P24409, P25228, P29687, P31582, P31583, P34213, P35276, P35278, P35279, P35280, P35292, P36017, P36586, P36863, P49103, P49104, P51147, P51148, P53994, P55258, P61006, P61007, P61019, P61020

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
RAB6C	“down-regulates activity”	VPS13B	binding
RAB6C	“up-regulates activity”	VPS13B	binding
RAB6C	up-regulates	Neurite_outgrowth
KIF1C	“up-regulates quantity”	RAB6C	relocalization
RAB6C	up-regulates	Synaptic_vesicle_exocytosis

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 20 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RAB geranylgeranylation	8	86.5×	8e-13
RAB GEFs exchange GTP for GDP on RABs	8	62.1×	6e-12

GO biological processes:

GO term	Partners	Fold	FDR
intracellular protein transport	5	18.0×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	44
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

213 predictions. Top by Δscore:

Variant	Effect	Δscore
2:129980726:G:GT	donor_gain	0.9200
2:129981730:A:AG	acceptor_gain	0.8500
2:129981731:G:GG	acceptor_gain	0.8500
2:129980212:TTCAG:T	donor_loss	0.8300
2:129980213:TCAG:T	donor_loss	0.8300
2:129980214:CAGG:C	donor_loss	0.8300
2:129980215:AG:A	donor_loss	0.8300
2:129980216:GGT:G	donor_loss	0.8300
2:129980217:G:C	donor_loss	0.8300
2:129980218:T:A	donor_loss	0.8300
2:129981731:GAA:G	acceptor_gain	0.8200
2:129980718:C:A	donor_gain	0.7300
2:129980715:A:AG	donor_gain	0.7000
2:129980716:G:GG	donor_gain	0.7000
2:129980730:T:TA	donor_gain	0.7000
2:129982318:TACA:T	acceptor_gain	0.6800
2:129979780:GTCTC:G	donor_gain	0.6700
2:129979781:TCTCT:T	donor_gain	0.6700
2:129980287:G:C	acceptor_gain	0.6300
2:129982352:G:GC	acceptor_gain	0.5900
2:129979794:TGCGG:T	donor_gain	0.5800
2:129979824:G:T	donor_gain	0.5700
2:129980151:G:GT	donor_gain	0.5600
2:129980219:A:C	donor_loss	0.5600
2:129981731:GA:G	acceptor_gain	0.5500
2:129982314:TAAA:T	acceptor_gain	0.5500
2:129980462:G:GT	donor_gain	0.5300
2:129980807:A:G	donor_gain	0.5300
2:129982324:G:GT	acceptor_gain	0.5000
2:129982325:T:TT	acceptor_gain	0.5000

AlphaMissense

1655 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:129980569:T:C	F152L	0.883
2:129980571:T:A	F152L	0.883
2:129980571:T:G	F152L	0.883
2:129980416:T:C	F101L	0.871
2:129980418:C:A	F101L	0.871
2:129980418:C:G	F101L	0.871
2:129980155:T:C	F14L	0.847
2:129980157:C:A	F14L	0.847
2:129980157:C:G	F14L	0.847
2:129980212:T:C	F33L	0.808
2:129980214:C:A	F33L	0.808
2:129980214:C:G	F33L	0.808
2:129980614:T:C	F167L	0.783
2:129980616:T:A	F167L	0.783
2:129980616:T:G	F167L	0.783
2:129980167:T:C	F18L	0.760
2:129980169:C:A	F18L	0.760
2:129980169:C:G	F18L	0.760
2:129980548:G:C	A145P	0.736
2:129980263:T:C	F50L	0.724
2:129980265:T:A	F50L	0.724
2:129980265:T:G	F50L	0.724
2:129980227:T:C	F38L	0.719
2:129980229:T:A	F38L	0.719
2:129980229:T:G	F38L	0.719
2:129980436:G:C	W107C	0.701
2:129980436:G:T	W107C	0.701
2:129980434:T:A	W107R	0.686
2:129980434:T:C	W107R	0.686
2:129980387:T:A	V91E	0.673

dbSNP variants (sampled 300 via entrez): RS1000020366 (2:129978515 A>G), RS1002242624 (2:129978964 G>C,T), RS1002708225 (2:129979313 G>A,T), RS1002994759 (2:129980616 T>C), RS1004141129 (2:129981336 A>G), RS1007486446 (2:129978099 G>A), RS1009583368 (2:129978873 C>G,T), RS1009614535 (2:129978576 G>A), RS1011632452 (2:129981885 G>A,C), RS1012961508 (2:129982943 G>T), RS1013155561 (2:129982568 A>G), RS1016185077 (2:129982603 T>C), RS1017442780 (2:129977856 C>A,T), RS10177167 (2:129979796 C>A,T), RS1017829232 (2:129978124 A>C)

Disease associations

OMIM: gene MIM:612909 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002136_7	Periodontitis (PAL4Q3)	8.000000e-06
GCST002136_9	Periodontitis (PAL4Q3)	8.000000e-07
GCST007325_50	General risk tolerance (MTAG)	5.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008579	risk-taking behaviour

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression	1
cobaltous chloride	increases expression	1
pyrimidifen	decreases expression	1
pyrachlostrobin	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Decitabine	affects cotreatment, increases expression, affects binding, increases reaction	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	affects expression, affects response to substance, increases response to substance	1
Methotrexate	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	decreases expression	1
Tobacco Smoke Pollution	affects expression	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.